3D Global Biotech Inc.
3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts profess… Read more
3D Global Biotech Inc. (6808) - Net Assets
Latest net assets as of June 2025: NT$905.47 Million TWD
Based on the latest financial reports, 3D Global Biotech Inc. (6808) has net assets worth NT$905.47 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.06 Billion) and total liabilities (NT$152.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$905.47 Million |
| % of Total Assets | 85.57% |
| Annual Growth Rate | 12.6% |
| 5-Year Change | 101.57% |
| 10-Year Change | N/A |
| Growth Volatility | 88.3 |
3D Global Biotech Inc. - Net Assets Trend (2019–2024)
This chart illustrates how 3D Global Biotech Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 3D Global Biotech Inc. (2019–2024)
The table below shows the annual net assets of 3D Global Biotech Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$904.69 Million | +208.28% |
| 2023-12-31 | NT$293.47 Million | -13.84% |
| 2022-12-31 | NT$340.60 Million | -12.60% |
| 2021-12-31 | NT$389.71 Million | -13.17% |
| 2020-12-31 | NT$448.82 Million | -10.20% |
| 2019-12-31 | NT$499.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 3D Global Biotech Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23377400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$91.70 Million | 10.14% |
| Common Stock | NT$778.40 Million | 86.04% |
| Other Comprehensive Income | NT$1.80 Million | 0.20% |
| Other Components | NT$32.78 Million | 3.62% |
| Total Equity | NT$904.69 Million | 100.00% |
3D Global Biotech Inc. Competitors by Market Cap
The table below lists competitors of 3D Global Biotech Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
$56.52 Million |
|
Orthex Oyj
HE:ORTHEX
|
$56.52 Million |
|
Bank of San Francisco
OTCQX:BSFO
|
$56.55 Million |
|
UFLEX Limited
NSE:UFLEX
|
$56.56 Million |
|
REITMANS CDA LTD
F:CX40
|
$56.50 Million |
|
Panacea Biotec Limited
NSE:PANACEABIO
|
$56.46 Million |
|
Udaipur Cement Works Limited
NSE:UDAICEMENT
|
$56.45 Million |
|
Panda Financial Holding Corp Ltd
SHG:600599
|
$56.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 3D Global Biotech Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 293,467,000 to 904,690,000, a change of 611,223,000 (208.3%).
- Net income of 91,701,000 contributed positively to equity growth.
- New share issuances of 515,310,000 increased equity.
- Other comprehensive income increased equity by 1,804,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$91.70 Million | +10.14% |
| Share Issuances | NT$515.31 Million | +56.96% |
| Other Comprehensive Income | NT$1.80 Million | +0.2% |
| Other Changes | NT$2.41 Million | +0.27% |
| Total Change | NT$- | 208.28% |
Book Value vs Market Value Analysis
This analysis compares 3D Global Biotech Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.80x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.70x to 2.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$9.68 | NT$35.80 | x |
| 2020-12-31 | NT$8.38 | NT$35.80 | x |
| 2021-12-31 | NT$7.22 | NT$35.80 | x |
| 2022-12-31 | NT$6.21 | NT$35.80 | x |
| 2023-12-31 | NT$5.22 | NT$35.80 | x |
| 2024-12-31 | NT$12.78 | NT$35.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 3D Global Biotech Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.14%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 34.51%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.15x
- Recent ROE (10.14%) is above the historical average (-10.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -7.43% | -199.79% | 0.04x | 1.04x | NT$-85.22 Million |
| 2020 | -10.68% | -361.35% | 0.03x | 1.08x | NT$-92.80 Million |
| 2021 | -15.32% | -539.10% | 0.03x | 1.09x | NT$-98.68 Million |
| 2022 | -19.70% | -491.72% | 0.04x | 1.09x | NT$-101.15 Million |
| 2023 | -19.75% | -280.87% | 0.06x | 1.10x | NT$-87.30 Million |
| 2024 | 10.14% | 34.51% | 0.26x | 1.15x | NT$1.23 Million |
Industry Comparison
This section compares 3D Global Biotech Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 3D Global Biotech Inc. (6808) | NT$905.47 Million | -7.43% | 0.17x | $56.51 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |